Abcam, ab240186, Anti-LIMPII antibody [EPR12080] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal LIMPII antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human, Mouse, Rat samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR12080,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab240186 is the carrier-free version of
ab176317
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LIMPII also known as LIMP-2 is a lysosomal membrane protein involved in the transport and degradation processes within cells. It has an approximate molecular mass of 54 kDa. LIMPII is mainly expressed in the lysosomal membranes of a variety of tissues notably in the kidney liver and spleen. Its structural characteristics enable it to function effectively within these cellular organelles delivering enzymes and other molecules essential for cellular maintenance and function.
Biological function summary
The protein plays a critical role in lipid and protein degradation and helps maintain cellular homeostasis. As part of the lysosomal membrane LIMPII facilitates the uptake and processing of large biomolecules into the lysosome. It functions as a receptor for the uptake of β-glucocerebrosidase forming a complex to assist in its proper delivery from the endoplasmic reticulum to the lysosomes. This receptor-ligand relationship ensures efficient enzymatic activity necessary for lipid metabolism.
Pathways
One finds that LIMPII participates in the sphingolipid metabolism pathway and is vital for glucosylceramide catabolism. It interacts with glucocerebrosidase in this pathway which plays a significant role in the metabolism of glycosphingolipids. Another pathway where LIMPII has importance is the autophagy pathway where it contributes to the fusion of autophagosomes with lysosomes. Its activity supports the turnover of cellular components maintaining cellular metabolic balance.
LIMPII's dysfunction has links to Gaucher's disease and atherosclerosis. Both conditions relate to improper lipid metabolism. In Gaucher's disease the interaction between LIMPII and glucocerebrosidase becomes disrupted leading to lysosomal storage issues. In contrast altered expressions of LIMPII correlate with atherosclerosis possibly due to its role in lipid processing. These associations suggest that LIMPII could be a significant factor in therapeutic approaches for these diseases.